Last10K.com

Anixa Biosciences Inc (ANIX) SEC Filing 10-Q Quarterly Report for the period ending Monday, January 31, 2022

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX
Cover - shares
3 Months Ended
Jan. 31, 2022
Mar. 11, 2022
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateJan. 31, 2022 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Current Fiscal Year End Date--10-31 
Entity File Number001-37492 
Entity Registrant NameANIXABIOSCIENCES, INC. 
Entity Central Index Key0000715446 
Entity Tax Identification Number11-2622630 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One3150 Almaden Expressway 
Entity Address, Address Line TwoSuite 250 
Entity Address, City or TownSan Jose 
Entity Address, State or ProvinceCA 
Entity Address, Postal Zip Code95118 
City Area Code(408) 
Local Phone Number708-9808 
Title of 12(b) SecurityCommon Stock, par value $.01 per share 
Trading SymbolANIX 
Security Exchange NameNASDAQ 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 30,152,319

View differences made from one quarter to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Other
Filter Subcategory:
All
Product
Expense
Cash Flow
Other
Inside Anixa Biosciences Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Shareholders' Equity (Unaudited)
Condensed Consolidated Statements Of Shareholders' Equity (Unaudited) (Parenthetical)
Accrued Expenses
Accrued Expenses (Tables)
Business And Funding
Business And Funding (Details Narrative)
Business And Funding (Tables)
Commitments And Contingences
Commitments And Contingences (Details Narrative)
Effect Of Recently Adopted And Issued Pronouncements
Fair Value Measurements
Fair Value Measurements (Tables)
Income Taxes
Income Taxes (Details Narrative)
Leases
Leases (Details Narrative)
Leases (Tables)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Details Narrative)
Schedule Of Accrued Expenses (Details)
Schedule Of Fair Value Measurements (Details)
Schedule Of Minimum Lease Payments (Details)
Schedule Of Noncontrolling Interest As A Component Of Equity (Details)
Schedule Of Operating Lease (Details)
Schedule Of Option Activity (Details)
Schedule Of Outstanding And Exercisable (Details)
Schedule Of Segment Information (Details)
Segment Information
Segment Information (Details Narrative)
Segment Information (Tables)
Stock Based Compensation
Stock Based Compensation (Details Narrative)
Stock Based Compensation (Tables)

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-006618
Submitted to the SEC: Fri Mar 11 2022 4:05:37 PM EST
Accepted by the SEC: Fri Mar 11 2022
Period: Monday, January 31, 2022
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001493152-22-006618.htm